AUTL
Autolus Therapeutics plc
Set alert
- YTD
- -23.62%
- 1 year
- +0.66%
- Open
- 1.58
- Prev close
- 1.58
- Mkt cap
- 404.57M
- Vol
- 1.68M
- Avg vol
- 2.27M
- EPS
- -1.06
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.48
- High
- 1.59
- Forward P/E
- -3.08
- Beta
- 0.00
- Short ratio
- 2.48
- Inst. own
- 77.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.39
- 200-d avg
- 4.08
- 1y target
- 10.45
Key statistics
- Market cap
- 598.77M
- Enterprise value
- 253.44M
- Trailing P/E
- 0.00
- Forward P/E
- -3.08
- PEG ratio
- 0.00
- Price / sales
- 59.34
- Price / book
- 1.25
- EPS (TTM)
- -1.22
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.09M
- Revenue growth
- 0.00%
- Free cash flow
- -171.18M
- Total cash
- 657.07M
- Total debt
- 301.17M
- Return on equity
- -82.20%
- Shares outstanding
- 266.12M
- Short % of float
- 3.19%
- 50-day average
- 3.39
- 200-day average
- 4.08
Analyst view
Consensus: strong buy
- Target (low)
- 7.60
- Target (mean)
- 10.45
- Target (high)
- 13.00
- Strong buy2
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.22411.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.21 | -0.31 | -0.10 | -47.62% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | -0.22 | -0.03 | -15.79% |
| Aug 8, 2024 | Jun 1, 2024 | -0.19 | — | — | — |
| May 17, 2024 | Mar 1, 2024 | -0.10 | -0.24 | -0.14 | -140.00% |
| May 17, 2024 | Mar 1, 2024 | -0.10 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -0.26 | -0.44 | -0.18 | -69.23% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Needham | reit | Buy | Buy |
| Dec 5, 2024 | Needham | reit | Buy | Buy |
| Nov 18, 2024 | Goldman Sachs | up | Neutral | Buy |
| Nov 15, 2024 | Redburn Atlantic | up | Neutral | Buy |
| Nov 13, 2024 | Needham | reit | Buy | Buy |
| Nov 12, 2024 | Needham | main | Buy | Buy |
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- autolus.com
News
- Autolus Therapeutics: Key Questions For The Near Term
- Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
- All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
- Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026
- Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
- Allarity Therapeutics (NASDAQ:ALLR) versus Autolus Therapeutics (NASDAQ:AUTL) Head to Head Analysis
- The FDA Grants Regenerative Medicine Advanced Therapy Designation to Autolus Therapeutics' Obecabtagene Autoleucel for Systemic Lupus Erythematosus and Lupus Nephritis
- Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
- Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
- Autolus Therapeutics Q2 Earnings Call Highlights
Your note
Sign in to keep a note on AUTL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wellington Management Group, LLP | 9.10% | 24,220,226 | 54.50M | Sep 29, 2024 |
| Blackstone Inc | 7.70% | 20,485,611 | 46.09M | Sep 29, 2024 |
| Syncona Portfolio Ltd | 6.97% | 18,554,624 | 41.75M | Sep 29, 2024 |
| FMR, LLC | 6.68% | 17,773,873 | 39.99M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.74% | 15,272,172 | 34.36M | Sep 29, 2024 |
| Avoro Capital Advisors LLC | 4.64% | 12,345,678 | 27.78M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 7.10% | 18,895,107 | 42.51M | Jul 30, 2024 |
| Fidelity Small Cap Growth Fund | 0.97% | 2,571,371 | 5.79M | Aug 30, 2024 |
| Fidelity Series Small Cap Opportunities Fund | 0.94% | 2,513,475 | 5.66M | Aug 30, 2024 |
| Price (T.Rowe) New Horizons Fund | 0.85% | 2,268,455 | 5.10M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.73% | 1,940,346 | 4.37M | Oct 30, 2024 |
| Fidelity Stock Selector Small Cap Fund | 0.64% | 1,706,679 | 3.84M | Aug 30, 2024 |